Investment Thesis
Amicus demonstrates strong revenue growth (+20% YoY) and solid operational cash generation ($33.1M), with excellent gross margins (88.5%) typical of pharmaceutical companies. However, the company remains unprofitable at the net level (-4.3% margin) despite positive operating income, and carries significant debt ($392.7M) relative to equity, requiring careful monitoring of cash burn and profitability trajectory.
Strengths
- Strong revenue growth of 20% YoY indicating market traction and potential product expansion
- Excellent gross margin of 88.5% demonstrating pricing power and operational efficiency
- Positive operating cash flow ($33.1M) and free cash flow ($29.8M) providing financial flexibility
- Healthy liquidity position with current ratio of 2.84x and $214M cash on hand
- Operating profitability ($32.8M) suggests core business viability
Risks
- Negative net income (-$27.1M) despite positive operations indicates significant non-operating expenses or tax impacts masking underlying profitability
- High leverage with debt-to-equity ratio of 1.43x and long-term debt of $392.7M relative to $274.2M equity creates financial risk
- Marginal interest coverage ratio of 2.6x leaves limited buffer for operational deterioration or interest rate increases
- Negative ROE (-9.9%) and ROA (-2.9%) indicate capital inefficiency and shareholder value destruction
- Low operating margin (5.2%) relative to industry standards suggests competitive pressures or high operating costs
Key Metrics to Watch
- Path to sustained net profitability and net margin expansion
- Debt reduction progress and trajectory toward more sustainable leverage ratios
- Revenue sustainability and whether 20% growth rate can be maintained
- Operating expense management and operating margin improvement
- Cash burn rate relative to free cash flow generation
Financial Metrics
Revenue
634.2M
Net Income
-27.1M
EPS (Diluted)
$-0.09
Free Cash Flow
29.8M
Total Assets
949.9M
Cash
214.0M
Profitability Ratios
Gross Margin
88.5%
Operating Margin
5.2%
Net Margin
-4.3%
ROE
-9.9%
ROA
-2.9%
FCF Margin
4.7%
Balance Sheet & Liquidity
Current Ratio
2.84x
Quick Ratio
1.88x
Debt/Equity
1.43x
Debt/Assets
71.1%
Interest Coverage
2.64x
Long-term Debt
392.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-25T05:04:11.522298 |
Data as of: 2025-12-31 |
Powered by Claude AI